Evidence map›Paper›PMID 33978304›Full record

ArticleThe journal of pathology. Clinical research2021

Dysbalance of ACE2 levels - a possible cause for severe COVID-19 outcome in COPD.

Elisabeth Fließer, Anna Birnhuber, Leigh M Marsh, Elisabeth Gschwandtner, Walter Klepetko, Horst Olschewski, Grazyna Kwapiszewska

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Association Between ACE2 and Lung Diseases.Infection and drug resistance · 2024
    Review
  4. Article
  5. COVID-19 in Patients with Chronic Lung Disease.Clinics in chest medicine · 2023
    Review
  6. Article
  7. Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elisabeth Fließer *Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.ORCID 0000-0002-2203-2981
Anna Birnhuber *Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Leigh M MarshLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Elisabeth GschwandtnerDivision of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Walter KlepetkoDivision of Thoracic Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Horst OlschewskiDivision of Pulmonology, Medical University of Graz, Graz, Austria.
Grazyna KwapiszewskaLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Ludwig Boltzmann Institute for Lung Vascular Research · ATMedical University of Graz · ATMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to healthcare systems worldwide. Binding of the virus to angiotensin-converting enzyme 2 (ACE2) is an important step in the infection mechanism. However, it is unknown if ACE2 expression in patients with chronic lung diseases (CLDs), such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary arterial hypertension (IPAH), or pulmonary fibrosis (PF), is changed as compared to controls. We used lung samples from patients with COPD (n = 28), IPAH (n = 10), and PF (n = 10) as well as healthy control donor (n = 10) tissue samples to investigate the expression of ACE2 and related cofactors that might influence the course of SARS-CoV-2 infection. Expression levels of the ACE2 receptor, the putative receptor CD147/BSG, and the viral entry cofactors TMPRSS2 (transmembrane serine protease 2), EZR, and FURIN were determined by quantitative PCR and in open-access RNA sequencing datasets. Immunohistochemical and single-cell RNA sequencing (scRNAseq) analyses were used for localization and coexpression, respectively. Soluble ACE2 (sACE2) plasma levels were analyzed by enzyme-linked immunosorbent assay. In COPD as compared to donor, IPAH, and PF lung tissue, gene expression of ACE2, TMPRSS2, and EZR was significantly elevated, but circulating sACE2 levels were significantly reduced in COPD and PF plasma compared to healthy control and IPAH plasma samples. Lung tissue expressions of FURIN and CD147/BSG were downregulated in COPD. None of these changes were associated with changes in pulmonary hemodynamics. Histological analysis revealed coexpression of ACE2, TMPRSS2, and Ezrin in bronchial regions and epithelial cells. This was confirmed by scRNAseq analysis. There were no significant expression changes of the analyzed molecules in the lung tissue of IPAH and idiopathic PF as compared to control. In conclusion, we reveal increased ACE2 and TMPRSS2 expression in lung tissue with a concomitant decrease of protective sACE2 in COPD patients. These changes represent the possible risk factors for an increased susceptibility of COPD patients to SARS-CoV-2 infection.

Indexed as

AdultAgedAngiotensin-Converting Enzyme 2BasiginCOVID-19Disease SusceptibilityFamilial Primary Pulmonary HypertensionFemaleFurinGene Expression RegulationHumansIdiopathic Pulmonary FibrosisLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveACE2 protein, humanAngiotensin-Converting Enzyme 2BasiginBSG protein, humanFurinSerine EndopeptidasesTMPRSS2 protein, humanACE2chronic lung diseasechronic obstructive pulmonary diseaseCOPDCOVID-19pulmonary fibrosispulmonary hypertensionSARS-CoV-2TMPRSS2

Identifiers

PMID33978304
PMCPMC8239572
OpenAlexW3163147065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.